Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Jounce Therapeutics, Inc. (JNCE)

0.8641   -0.044 (-4.79%) 12-06 10:24
Open: 0.84 Pre. Close: 0.9076
High: 0.917 Low: 0.84
Volume: 20,186 Market Cap: 45(M)

Technical analysis

as of: 2022-12-06 9:49:02 AM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 1.98     One year: 2.69
Support: Support1: 0.7    Support2: 0.58
Resistance: Resistance1: 1.69    Resistance2: 2.3
Pivot: 0.88
Moving Average: MA(5): 0.87     MA(20): 1.03
MA(100): 2.69     MA(250): 4.64
MACD: MACD(12,26): -0.3     Signal(9): -0.4
Stochastic oscillator: %K(14,3): 37     %D(3): 28
RSI: RSI(14): 28.5
52-week: High: 8.8  Low: 0.7
Average Vol(K): 3-Month: 329 (K)  10-Days: 340 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ JNCE ] has closed above bottom band by 30.0%. Bollinger Bands are 80.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.93 - 0.93 0.93 - 0.93
Low: 0.81 - 0.81 0.81 - 0.82
Close: 0.9 - 0.91 0.91 - 0.91

Company Description

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.

Headline News

Tue, 22 Nov 2022
Finance Stocks Lead Highs Tuesday; Markets Rise - InvestorsObserver

Fri, 11 Nov 2022
NVIDIA To $225? Plus Raymond James Cuts PT On This Stock By 81% By Benzinga - UK

Fri, 11 Nov 2022
Jounce downgraded to outperform at Raymond James on timing for data on immunotherapy - Seeking Alpha

Thu, 10 Nov 2022
Jounce Therapeutics Tops Q3 EPS by 2c By -

Thu, 10 Nov 2022
Jounce Therapeutics, Inc. (JNCE) Q3 2022 Results - Earnings Call Transcript - Seeking Alpha

Wed, 09 Nov 2022
Notable earnings before Thursday's open - Seeking Alpha

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 52 (M)
Shares Float 25 (M)
% Held by Insiders 20 (%)
% Held by Institutions 83 (%)
Shares Short 1,470 (K)
Shares Short P.Month 2,000 (K)

Stock Financials

EPS -1.99
EPS Est Next Qtl -0.35
EPS Est This Year -0.63
EPS Est Next Year -0.19
Book Value (p.s.) 2.5
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -37.9
Return on Equity (ttm) -69.5
Qtrly Rev. Growth 0
Gross Profit (p.s.) -0.35
Sales Per Share 0
EBITDA (p.s.) -2.53
Qtrly Earnings Growth 0
Operating Cash Flow -116 (M)
Levered Free Cash Flow -69 (M)

Stock Valuations

PE Ratio -0.43
PEG Ratio 0
Price to Book value 0.33
Price to Sales 0
Price to Cash Flow -0.38

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.